In many ways, the role of the genetic counselor working with patients and families with a lysosomal storage disease is similar to a counselor in other pediatric and adult counseling situations. The goals of counseling; education, access to health care, and supportive counseling are the same. Although the goals of counseling are simply stated, an effective counseling session is always a complex interaction. It is an empathic exchange where the counselor promotes understanding of the particular disease, the inheritance pattern, takes a family history, provides recurrence risks, and reviews diagnostic testing, disease management issues, and supportive resources, while simultaneously learning about family structure, dynamics, and the impact of the diagnosis. The counselor assesses the level of understanding about the disease and the appropriate resources to assist the patient and family facing an inherited disease. A balance of teaching and counseling and the ability to be flexible and responsive to the counselee is key for achieving an effective interaction. The chapter is designed as a resource for counselors or other health care providers interested in an update on counseling issues for this group of treatable lysosomal storage diseases. Six genetic counselors who have been involved with the lysosomal storage disease community for the last decade draw on their counseling expertise to provide a disease summary and clinical counseling pearls for Gaucher disease, Fabry disease, Mucopolysaccharidosis (MPS) type 1, MPS II, MPS VI, and Pompe disease.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Amartino, H. Painceira, D. Pomponio, R.J. Niizawa, G. Sabio Paz, V. Blanco, M.A. Chamoles, N.A. (2006). Two clinical forms of glycogen-storage disease type II in two generations of the same family. Clin Genet 69:187-188.
An, Y. Young, S.P. Kishnani, P.S. Millington, D.S. Amalfitano, A. Corzo, D. Chen, Y.T. (2005). Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease. Mol Genet Metab 85:247-254.
Ausems, M.G. Verbiest, J. Hermans, M.P. Kroos, M.A. Beemer, F.A. Wokke, J.H. Sandkuijl, L.A. Reuser, A.J. van der Ploeg, A.T. (1999). Frequency of glycogen storage disease type II in The Netherlands: Implications for diagnosis and genetic counselling. Eur J Hum Genet 7:713-716.
Barranger, J.A. Ginns, E.I. (1989) Glucosylceramide lipidosis: Gaucher disease. In: Scriver, C.R. Beaudet, A. Sly, W.S. Valle, D. (Eds). The Metabolic Basis of Inherited Disease. 6th ed. New York: McGraw-Hill; pp. 1677-1698.
Barranger, J.A. O’Rourke, E. (2001). Lessons learned from the development of enzyme replacement therapy for Gaucher disease. J Inherit Metab Dis 24 Supp 2:87-96.
Bennett, R.L, Hart, K. O’Rourke, E, Barranger, J.A. Johnson, J, MacDermot, K.D. Pastores, G.M. Steiner R.D. Tadhani R. (2002). Fabry Disease in Genetic Counseling Practice: Recommendations of the National Society of genetic Counselors. J Genet Counsel. 11:121-146.
Brady, R.O. Grabowski, G.A. Thadhani, R. (2000). Fabry disease: α-galactosidase A deficiency. Gardiner-Caldwell SynderMed 1-8.
Brady, R.O. Murray, G.J. Moore, D.F. Schiffmann, R. (2001). Enzyme replacement therapy in Fabry disease. J Inher Metab Dis 24 Supp 2:18-24.
Case, L.E. Kishnani, P.S. (2006). Physical therapy management of Pompe disease. Genet Med 8:318-327.
Charrow, J. Andersson, H.C. Kaplan, P. Kolodny, E.H. Pastores, G.M. et al. (2004). Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: Consensus recommendations. J Pediatr 144:112-120.
Cox, T. Lachmann, R. Hollak, C. Aerts, J. van Weely, S. Hrebicek, M. Platt, F.M, Butters, T.D Dwek, R. Moyses, C. Gow, I. Elstein, D. Zimran, A. (2000). Novel oral treatment of Gaucher’s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet, 355:1481-1485.
Damiano, A.M.Pastores, G.M. Ware, J.E. (1998) The health related quality of life of adults with Gaucher’s disease receiving enzyme replacement therapy: Results from a retrospective study. Qual Life Res 7:373-86.
Desnick, R.J. Brady, R.O. Barranger, J.A. Collins, A.J. Germain, D.P. Goldman, M. Grabowski, G.A. Packman, S. Wilcox, W.R. (2003). Fabry disease, an under-reco-gnized multisystemic disorder: Expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 138:338-346.
Elstein, D. Hollak, C.E. Aerts, J.M. vanWeely, S. Maas, M. Cox, T.M. Lachmann, R.H. Hrebicek, M. Platt, F.M. Butters, T.D. Dwek, R.A. Zimran, A. (2004). Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J Inherit Metab Dis 27:757-766.
Eng, C.M. Guffon, N. Wilcox, W.R. Germain, D.P, Lee, P. Waldek, S. Caplan, L. Linthorst, G.E. Desnick, R.J. (2001). Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry’s disease. N Eng J Med 345: 9-16.
Grabowski, G.A. Beutler, E. (2001). Gaucher disease. In: Scriver C, Beaudet A, Sly W, Valle D, Childs B, Kinzler K (Eds). The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill; pp. 3635-3638.
Grewal SS, Wynn R, Abdenur JE, Burton BK, Gharib M, Haase C, Hayashi RJ, Shenoy S, Sillence D, Tiller GE, Dudek ME, van Royen-Kerkhof A, Wraith JE, Woodard P, Young GA, Wulffraat N, Whitley CB, Peters C. (2005). Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome. Genet Med 7: 143-146.
Hagemans, M.L. Janssens, A.C. Winkel, L.P. Sieradzan, K.A. Reuser, A.J. Van Doorn, P.A. Van der Ploeg, A.T. (2004). Late-onset Pompe disease primarily affects quality of life in physical health domains. Neurology 63:1688-1692.
Hagemans, M.L. Winkel, L.P. Hop, W.C. Reuser, A.J. Van Doorn, P.A. Van der Ploeg, A.T. (2005). Disease severity in children and adults with Pompe disease related to age and disease duration. Neurology 64:2139-2141.
Harmatz, P. Ketteridge, J. Giugliani, R. Guffon, N. Teles, E. Miranda, S, Swiedler, S. Hopwood, J.J. (2005). Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): Results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics 115, e681-e689.
Harmatz, P. Whitley, C.B. Waber, L. Pais, R. Steiner, R. Plecko, B. Kaplan, P. Simon, J. Butensky, E. Hopwood, J.J. (2004). Enzyme replacement therapy in mucopoly-saccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr 144(5):574-580.
Hermans, M.M. van Leenen, D. Kroos, M.A. Beesley, C.E. Van Der Ploeg, A.T. Sakuraba, H. Wevers, R. Kleijer, W. Michelakakis, H. Kirk, EP. Fletcher, J. Bosshard, N. Basel-Vanagaite, L. Besley, G. Reuser, A.J. (2004). Twenty-two novel mutations in the lysosomal alpha-glucosidase gene (GAA) underscore the genotype-phenotype correlation in glycogen storage disease type II. Hum Mutat 23:47-56.
Hoefsloot, L.H. van der Ploeg, A.T. Kroos, M.A. Hoogeveen-Westerveld, M. Oostra, B.A. Reuser, A.J. (1990). Adult and infantile glycogenosis type II in one family, explained by allelic diversity. Am J Hum Genet 46:45-52.
Kakkis E, McEntee M, Vogler C, Le S, Levy B, Belichenko P, Mobley W, Dickson P, Hanson S, Passage M. (2004). Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I, Mol Genet Metab 83:163-174.
Kishnani, P. Corzo, D. Nicolino, M. Byrne, B. Mandel, H. Hwu, W.L. Leslie, N. Levine, J. Spencer, C. McDonald, M. Li J, DuMontier, J. Michael, H. Chien, Y.H. Hopkin, R. Vijayaraghavan, S. Gruskin, D. Bartholomew, D. van der Ploeg, A. Clancy, J.P. Parini, R. Morin, G. Beck, M. Delagastine, G. S. Jokic, M. Thurberg, B. Richards, S. Bali, D. Davison, M. Worden, M. Chen, Y.T. Wraith, J.E. (2007). Recombinant human acid α-glucosidase: Major clinical benefits in infantile-onset Pompe disease. Neurology 68:99-109.
Kishnani, P.S. Howell, R.R. (2004). Pompe disease in infants and children. J Pediatr 144:S35-43.
Kishnani, P.S. Hwu, W.L. Mandel, H. Nicolino, M. Yong, F. Corzo, D. (2006). A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 148:671-676.
Kishnani, P.S. Steiner, R.D. Bali, D. Berger, K. Byrne, B.J. Case, L.E. Crowley, J.F. Downs, S. Howell, R.R. Kravitz, R.M. Mackey, J. Marsden, D. Martins, A.M. Millington, D.S. Nicolino, M. O’Grady, G. Patterson, M.C. Rapoport, D.M. Slonim, A. Spencer, C.T. Tifft, C.J. Watson, M.S. (2006). Pompe disease diagnosis and management guideline. Genet Med 8:267-288.
Li, Y. Scott, C.R. Chamoles, N.A. Ghavami, A. Pinto, B.M. Turecek, F. Gelb, M.H. (2004). Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening. Clin Chem 50:1785-1796.
Litjens, T. Hopwood, J.J. (2001) Mucopolysaccharidosis type VI: Structural and clinical implications of mutations in N-acetylgalactosamine-4-sulfatase. Hum Mutat 18:282-295.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
O'Rourke, E., Laney, D., Morgan, C., Mooney, K., Sullivan, J. (2007). Genetic Counseling for Lysosomal Storage Diseases. In: Lysosomal Storage Disorders. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-70909-3_13
Download citation
DOI: https://doi.org/10.1007/978-0-387-70909-3_13
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-70908-6
Online ISBN: 978-0-387-70909-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)